Výsledky vyhledávání

Akademický článek

Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials

Autor: Gabrail N, Yanagihara R, Spaczyński M, Cooper W, O’Boyle E, Smith C, Boccia R

Publikováno v: Cancer Management and Research, Vol 2015, Iss default, Pp 83-92 (2015)

Nashat Gabrail,1 Ronald Yanagihara,2 Marek Spaczyński,3 William Cooper,4 Erin O'Boyle,5 Carrie Smith,1 Ralph Boccia6 1Gabrail Cancer Center, Canton, OH, USA; 2St Louise Regional Hospital, Gilroy, CA, USA; 3Department of Gynecology, Obstetrics and Gy

Externí odkaz: https://doaj.org/article/1c5daf4d22124b0287628741b6205111

Zobrazit plný text záznamu

Akademický článek

Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron

Autor: Ottoboni T, Gelder MS, O’Boyle E

Publikováno v: Journal of Experimental Pharmacology, Vol 2014, Iss default, Pp 15-21 (2014)

Thomas Ottoboni,1 Mark S Gelder,1 Erin O’Boyle2 1Heron Therapeutics, Inc., Redwood City, CA, USA; 2FibroGen, Inc., San Francisco, CA, USA Abstract: Granisetron and other 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are first-line agents

Externí odkaz: https://doaj.org/article/8ad3fdf4607041b89895938cf8ec8c67

Zobrazit plný text záznamu

Akademický článek

A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation

Autor: Mason JW, Moon TE, O’Boyle E, Dietz A

Publikováno v: Cancer Management and Research, Vol 2014, Iss default, Pp 181-190 (2014)

Jay W Mason,1 Thomas E Moon,2 Erin O’Boyle,3 Albert Dietz41Department of Medicine, University of Utah, Salt Lake City, UT, 2Tarizona eHealth Services, Inc., San Carlos, CA, 3AP Pharma, Redwood City, CA, 4Spaulding Clinical Research, West Bend, WI,

Externí odkaz: https://doaj.org/article/d19432b8666f4c6795f0471f0d2c9cc2

Zobrazit plný text záznamu